Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug combinations for non-small lung cancer (NSCLC). The CONCORDE study is looking at the addition of DNA damage repair inhibitors with radical radiotherapy for stage III NSCLC, whereas the SPITFIRE explores the immunomodulating effects of stereotactic radiation in combination with immunotherapy in stage IV disease. These combinations have the potential to replace standard chemotherapy, with futher research needed. This video was recorded at the UK Oncology Forum (OF) 2018, held in Liverpool, UK.
